Methods Study design STEP-HFpEF (NCT04788511) was a randomized, international, double-blind, placebo-controlled trial that examined the efficacy and safety of semaglutide 2.4 mg once weekly compared to placebo in patients with the obesity phenotype of HFpEF without diabetes 11
During the fifth voting round, a final questionnaire with updated grading for the seven recommendations was disseminated to the group, and 100% consensus was achieved with 16 out of 16 questionnaires returned (Box 1)
In the meantime, Lilly developed a dual agonist approach with tirzepatide, which targets GLP-1 receptors plus (Gastric inhibitory polypeptide (GIP), and which shows strong efficacy (high teens when placebo adjusted at 72 weeks)
132,133 The age of infected individuals is the next medically significant risk factor after T2D and overweight that is connected to a potential relationship between DPP4 and vulnerability to SARS-CoV-2 illness
Additionally, patients are required to draw their own doses from a vial using insulin syringes, which requires careful unit-to-milligram conversion calculations